<DOC>
	<DOCNO>NCT01117623</DOCNO>
	<brief_summary>Continuous dose BAY73-4506 patient advance cancer</brief_summary>
	<brief_title>Continuous Dosing BAY73-4506 Patients With Advanced Malignancies</brief_title>
	<detailed_description />
	<criteria>18 year Patients advance , histologically cytologically confirm solid tumor , malignant lymphoma , multiple myeloma refractory standard therapy Radiographical , hematological clinically evaluable tumor Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Life expectancy least 12 week Adequate bone marrow , liver , renal function assess follow laboratory requirement : Total bilirubin less equal 1.5 x upper limit normal ( ULN ) Signed informed consent must obtain prior study specific procedure History cardiac disease : congestive heart failure ( CHF ) &gt; New York Heart Association ( NYHA ) Class II ; active coronary artery disease , myocardial infarction within 6 month prior study entry ; new onset angina within 3 month unstable angina cardiac arrhythmia require antiarrhythmic therapy ( beta blocker digoxin permit ) Uncontrolled hypertension define systolic blood pressure &gt; 150 mm Hg and/or diastolic blood pressure &gt; 90 mmHg , despite optimal medical management History HIV infection chronic hepatitis B C Active clinically serious infection ( &gt; Grade 2 NCI Common Terminology Criteria Adverse Events v3.0 ) Symptomatic metastatic brain meningeal tumor unless patient &gt; 6 month definitive therapy , evidence tumor growth image study within 2 week prior study entry clinically stable respect tumor time study entry . Patients brain metastasis must undergo acute steroid therapy steroid taper ( chronic steroid therapy acceptable provide dose stable one month prior follow screen radiographic study ) Substance abuse , medical , psychological social condition may interfere patient178s participation study evaluation study result Radiotherapy target lesion within 3 week prior Day 1 , Cycle 1 ( first dose study drug ) . ( Palliative radiotherapy allow ) . Radiotherapy target lesion study regard progressive disease Previous concurrent cancer distinct primary site histology cancer evaluate study EXCEPT cervical carcinoma situ , treat basal cell carcinoma , superficial bladder tumor [ Ta , Tis T1 ] cancer curatively treat &gt; 3 year prior study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Oncology patient advance disease</keyword>
	<keyword>BAY73-4506</keyword>
</DOC>